The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME)

Transfusion

Volumn 54, Issue 6, 2014, Pages 1523-1529

  Tobian, Aaron A R ^a   Fuller, Alice K ^a   Uglik, Kristin ^a   Tisch, Daniel J ^b   Borge, Prabhakar D ^c   Benjamin, Richard J ^c   Ness, Paul M ^a   King, Karen E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Amercian Red Cross   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD DERIVATIVE; DIPHENHYDRAMINE; GRANULOCYTE ANTIBODY; HLA ANTIGEN CLASS 2; PLATELET ADDITIVE SOLUTION; RANITIDINE; UNCLASSIFIED DRUG;

ALLERGIC TRANSFUSION REACTION; APHERESIS; ARTICLE; BLOOD TRANSFUSION REACTION; BODY SURFACE; CELLULAR PARAMETERS; CORRECTED COUNT INCREMENT; FEBRILE NONHEMOLYTIC TRANSFUSION REACTION; HUMAN; HYPOTENSION; INCIDENCE; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE TRANSFUSION; TRANSFUSION RELATED ACUTE LUNG INJURY;

BLOOD COMPONENT REMOVAL; BLOOD PLATELETS; HUMANS; MODELS, THEORETICAL; PLATELET TRANSFUSION; RETROSPECTIVE STUDIES;

EID: 84902297802     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12498     Document Type: Article

References (49)

1. Domen RE, Hoeltge GA,. Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med 2003; 127: 316-320.
2. Enright H, Davis K, Gernsheimer T, etal. Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial. Transfusion 2003; 43: 1545-1552.
3. Roback J, Combs MR, Grossman B, etal. editors. Technical manual. 16th ed. Bethesda (MD): American Association of Blood Banks; 2008.
4. Tobian AA, King KE, Ness PM,. Transfusion premedications: a growing practice not based on evidence. Transfusion 2007; 47: 1089-1096.
5. Vyas GN, Perkins HA, Fudenberg HH,. Anaphylactoid transfusion reactions associated with anti-IgA. Lancet 1968; 2: 312-315.
6. Savage WJ, Tobian AA, Fuller AK, etal. Allergic transfusion reactions to platelets are associated more with recipient and donor factors than with product attributes. Transfusion 2011; 51: 1716-1722.
7. Savage WJ, Tobian AA, Savage JH, etal. Atopic predisposition of recipients in allergic transfusion reactions to apheresis platelets. Transfusion 2011; 51: 2337-2342.
8. Savage WJ, Tobian AA, Savage JH, etal. Scratching the surface of allergic transfusion reactions. Transfusion 2013; 53: 1361-1371.
9. Shimada E, Tadokoro K, Watanabe Y, etal. Anaphylactic transfusion reactions in haptoglobin-deficient patients with IgE and IgG haptoglobin antibodies. Transfusion 2002; 42: 766-773.
10. Tobian AA, Savage WJ, Tisch DJ, etal. Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction. Transfusion 2011; 81: 1676-1683.
11. Karafin M, Fuller AK, Savage WJ, etal. The impact of apheresis platelet manipulation on corrected count increment. Transfusion 2012; 52: 1221-1227.
12. Kerkhoffs JL, Eikenboom JC, Schipperus MS, etal. A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood 2006; 108: 3210-3215.
13. Alhumaidan H, Sweeney J,. Current status of additive solutions for platelets. J Clin Apher 2012; 27: 93-98.
14. de Wildt-Eggen J, Nauta S, Schrijver JG, etal. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion 2000; 40: 398-403.
15. Sweeney J,. Additive solutions for platelets: is it time for North America to go with the flow? Transfusion 2009; 49: 199-201.
16. Kacker S, Ness PM, Savage WJ, etal. The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions. Transfusion 2013; 53: 2609-2618.
17. Fuller AK, Uglik KM, Braine HG, etal. A comprehensive program to minimize platelet outdating. Transfusion 2011; 51: 1469-1476.
18. Centers for Disease Control and Prevention. National Healthcare Safety Network Biovigilance Component Hemovigilance Model Surveillance Model, 2013. [cited 2013 Nov 7]. Available from: http://www.cdc.gov/nhsn
19. Azuma H, Hirayama J, Akino M, etal. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol). Transfusion 2009; 49: 214-218.
20. Slichter SJ, Bolgiano D, Corson J, etal. Extended storage of platelet-rich plasma-prepared platelet concentrates in plasma or Plasmalyte. Transfusion 2010; 50: 2199-2209.
21. Adams GA, Swenson SD, Rock G,. Survival and recovery of human platelets stored for five days in a non-plasma medium. Blood 1986; 67: 672-675.
22. Heaton WA, Holme S, Keegan T,. Development of a combined storage medium for 7-day storage of platelet concentrates and 42-day storage of red cell concentrates. Br J Haematol 1990; 75: 400-407.
23. Holme S, Heaton WA, Courtright M,. Improved in vivo and in vitro viability of platelet concentrates stored for seven days in a platelet additive solution. Br J Haematol 1987; 66: 233-238.
24. Holme S, Heaton WA, Whitley P,. Platelet storage lesions in second-generation containers: correlation with in vivo behavior with storage up to 14 days. Vox Sang 1990; 59: 12-18.
25. Vassallo RR, Adamson JW, Gottschall JL, etal. In vitro and in vivo evaluation of apheresis platelets stored for 5 days in 65% platelet additive solution/35% plasma. Transfusion 2010; 50: 2376-2385.
26. van Rhenen DJ, Gulliksson H, Cazenave JP, etal. Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution. Transfus Med 2004; 14: 289-295.
27. Kerkhoffs JL, van Putten WL, Novotny VM, etal., Dutch-Belgian HOVON cooperative group. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150: 209-217.
28. Vamvakas EC, Pineda AA,. Allergic and anaphylactic reactions. In:, Popovsky MA, editor. Transfusion reactions. Bethesda (MD): American Association of Blood Banks Press; 2001. p. 83-127.
29. Koda Y, Watanabe Y, Soejima M, etal. Simple PCR detection of haptoglobin gene deletion in anhaptoglobinemic patients with antihaptoglobin antibody that causes anaphylactic transfusion reactions. Blood 2000; 95: 1138-1143.
30. Lambin P, Le Pennec PY, Hauptmann G, etal. Adverse transfusion reactions associated with a precipitating anti-C4 antibody of anti-Rodgers specificity. Vox Sang 1984; 47: 242-249.
31. O'Neill GJ, Yang SY, Tegoli J, etal. Chido and Rodgers blood groups are distinct antigenic components of human complement C4. Nature 1978; 273: 668-670.
32. Schmidt AP, Taswell HF, Gleich GJ,. Anaphylactic transfusion reactions associated with anti-IgA antibody. N Engl J Med 1969; 280: 188-193.
33. Savage WJ, Savage JH, Tobian AA, etal. Allergic agonists in apheresis platelet products are associated with allergic transfusion reactions. Transfusion 2012; 52: 575-581.
34. Ramirez MA,. Horse asthma following blood transfusion. JAMA 1919; 73: 984-985.
35. Michel J, Sharon R,. Non-haemolytic adverse reaction after transfusion of a blood unit containing penicillin. Br Med J 1980; 280: 152-153.
36. Sharon R, Kidroni G, Michel J,. Presence of aspirin in blood units. Vox Sang 1980; 38: 284-287.
37. Poothullil J, Shimizu A, Day RP, etal. Anaphylaxis from the product(s) of ethylene oxide gas. Ann Intern Med 1975; 82: 58-60.
38. Win N, Chapman CE, Bowles KM, etal. How much residual plasma may cause TRALI? Transfus Med 2008; 18: 276-280.
39. Josephson CD, Castillejo MI, Grima K, etal. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies. Transfus Apher Sci 2010; 42: 83-88.
40. Quillen K, Sheldon SL, Daniel-Johnson JA, etal. A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies. Transfusion 2011; 51: 92-96.
41. Mair B, Benson K,. Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets. Transfusion 1998; 38: 51-55.
42. Larsson LG, Welsh VJ, Ladd DJ,. Acute intravascular hemolysis secondary to out-of-group platelet transfusion. Transfusion 2000; 40: 902-906.
43. Karafin MS, Blagg L, Tobian AA, etal. ABO antibody titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions. Transfusion 2012; 52: 2087-2093.
44. American Association of Blood Banks. Standards for blood banks and transfusion services. 26th ed. Bethesda (MD): American Association of Blood Banks Press; 2009.
45. Patterson BJ, Freedman J, Blanchette V, etal. Effect of premedication guidelines and leukoreduction on the rate of febrile nonhaemolytic platelet transfusion reactions. Transfus Med 2000; 10: 199-206.
46. Ezidiegwu CN, Lauenstein KJ, Rosales LG, etal. Febrile nonhemolytic transfusion reactions. Management by premedication and cost implications in adult patients. Arch Pathol Lab Med 2004; 128: 991-995.
47. Sanders RP, Maddirala SD, Geiger TL, etal. Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children. Br J Haematol 2005; 130: 781-787.
48. Kennedy LD, Case LD, Hurd DD, etal. A prospective, randomized, double blind controlled trial of acetaminophen and diphenhydramine premedication versus placebo for the prevention of transfusion reactions. Transfusion 2008; 48: 2285-2291.
49. Wang SE, Lara PN, Jr, Lee-Ow A, etal. Acetaminophen and diphenhydramine as premedication for platelet transfusions: a prospective randomized double-blind placebo-controlled trial. Am J Hematol 2002; 70: 191-194.